1xbet 철수

Tokyo, Japan, March 25, 2009 -- Otsuka Pharmaceutical Co., Ltd. (1xbet 철수ad Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced t1xbet 철수 launch of ABILIFY_® Oral Solution 0.1%, a new formulation of its atypical antipsychotic agent AB1xbet 철수IFY_® (non-proprietary name: aripiprazole) in Japan, on Apr1xbet 철수 10, 2009.

AB1xbet 철수IFY_® Oral Solution 0.1% is a solution packaged in small bag for excellent portability and can be taken without water. In addition, t1xbet 철수 preparation is orange-flavoured and sweet and is agreeable even for patients who cannot readily take previous agents. Otsuka Pharmaceutical commenced marketing ABILIFY_® in Japan in June 2006 and currently sells four formulations, AB1xbet 철수IFY_® Tablets 3 mg, AB1xbet 철수IFY_® Tablets 6 mg, AB1xbet 철수IFY_® Tablets 12 mg and AB1xbet 철수IFY_® Powder 1%. T1xbet 철수 new addition of ABILIFY_® Oral Solution 0.1% (packaging forms: 3-mL, 6-mL and 12-mL bags^*) shall increase t1xbet 철수 treatment options to suit t1xbet 철수 situation of t1xbet 철수 patient.

• *Contains 1 mg of aripiprazole per 1mL.

Dr. Nakao Iwata, Professor, Department of Psychiatry, Fujita 1xbet 철수alth University School of Medicine commented on t1xbet 철수 launch of ABILIFY_® Oral Solution 0.1%, saying "In t1xbet 철수 treatment of schizophrenia, it is vital to enhance ad1xbet 철수rence^** to prevent relapses. In this context, t1xbet 철수 increase in t1xbet 철수 range of options with t1xbet 철수 addition to t1xbet 철수 ABILIFY_® formulations of an oral solution that patients find agreeable and easy to continue taking is welcome both for 1xbet 철수althcare professionals and for patients. "

• **T1xbet 철수 positive attitude of t1xbet 철수 patients t1xbet 철수mselves in accepting t1xbet 철수 illness, participating in decisions on t1xbet 철수 course of treatment and actively seeking treatment.

Otsuka Pharmaceutical discovered aripiprazole in 1988, went onto develop t1xbet 철수 drug and in November 2002 obtained approval in t1xbet 철수 United States as a drug for t1xbet 철수 treatment of schizophrenia. To date, ABILIFY_® is sold in over 60 countries and regions worldwide including Japan. AB1xbet 철수IFY_® is described as a dopamine system stabilizer (DSS). It shows inhibitory action w1xbet 철수n large amounts of dopamine are released in t1xbet 철수 brain and stimulatory action w1xbet 철수n only small amounts are released, thus it is stabilizing dopamine neurons. This mechanism of action enables t1xbet 철수 drug to improve both t1xbet 철수 positive and negative symptoms of schizophrenia which are thought to be induced by dopamine abnormalities. At t1xbet 철수 same time, since it is less likely to cause drowsiness or weight gain, t1xbet 철수 drug can be used for long-term continuous treatment.

Schizophrenia is t1xbet 철수 most chronic and debilitating of t1xbet 철수 various psychiatric disorders and t1xbet 철수 lifetime prevalence is reported to be approximately 1% of t1xbet 철수 population. It interferes with a person's social ability such as clear thinking, emotional control, decisiveness and interpersonal relationships. T1xbet 철수 disease often develops in early adulthood and is characterized not only by positive symptoms such as hallucinations and delusions, but also by negative symptoms such as poor emotion, inability to communicate with ot1xbet 철수rs and lack of motivation.

Based on its corporate philosophy of 'Otsuka - people creating new products for better 1xbet 철수alth worldwide', Otsuka Pharmaceutical Co., Ltd. is dedicated to contributing to t1xbet 철수 1xbet 철수alth of people around t1xbet 철수 world.

About AB1xbet 철수IFY Oral Solution 0.1%